Edmonton, AB (CVQ:TSX-VEN) CV Technologies Inc. Board Chair - Gordon Tallman - today announced that the board has voted to confirm the appointment of company co-founder Dr. Jacqueline Shan to the position of CEO. Dr. Shan had been serving as interim CEO. She will remain company President and Chief Scientific Officer. Her involvement from the inception of the company to today ensures that CV Technologies will remain committed to the development and sale of its scientifically based natural health products..
Mr. Tallman said, "The board wanted to recognize the extraordinary contributions Dr. Shan has made to the company stretching back to the days when she helped to found it." He added, "Dr. Shan has been a key contributor to remarkable achievements in our past and we believe she will do the same at a time of significant expansion for CVT. She has recruited specialists to help her enhance the functionality of our business, focusing on the key areas of sales, marketing, media coverage, investor relations and finance."
Dr. Shan said, "I'm very pleased with the progress we've made since our last annual meeting, the team I've assembled is firing on all cylinders." And she added, "I think our shareholders have lots to celebrate with the two major announcements we've made in recent weeks."
Dr. Shan is co-founder of CV Technologies and the co-discoverer of COLD-fX(R) an anti-cold, anti-flu product which clinical trials show reduces the risk of getting colds and flu by 89%. She is both a pharmacologist and physiologist and is recognized by universities in three countries. At the age of 15 she entered university in China in pursuit of the first of two doctorates she has received - one from the University of Alberta in Canada, and the other from Peking Union Medical College - China's leading medical school. She is also a member of the distinguished Chinese Academy of Medical Sciences, the holder of 10 patents, the author or contributor to 50 peer reviewed articles and an international guest speaker.
ABOUT CV TECHNOLOGIES INC.
CV Technologies, founded in 1992, aims to become a global leader in the development, distribution, marketing and selling of safe and effective natural health products for disease prevention and health maintenance. CV's products are unique because they are developed and standardized according to the company's ChemBioPrint(TM) technology, a patented process that precisely identifies the chemical profile and biological activity of natural health products. This is a combination of chemical and pharmacological fingerprinting that ensures each batch of product delivers verifiable and provable health benefits, and is both safe and consistent with previous batches.